Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis-Reference-Cited by-同舟云学术

Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis

Published:2022-05-11 Issue:6 Volume:12 Page:1481-1491
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

de Bruin-Weller Marjolein S.,Serra-Baldrich Esther,Barbarot Sebastien,Grond Susanne,Schuster Christopher,Petto Helmut,Capron Jean-Philippe,Raibouaa Afaf,Werfel Thomas

Funder

Eli Lilly and Company

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

https://link.springer.com/content/pdf/10.1007/s13555-022-00734-w.pdf

Reference28 articles.

1. European Medicines Agency. EMA/505843/2020: An overview of Olumiant and why it is authorised in the EU. Amsterdam: European Medicines Agency; 2017, 23 November 2017.

2. Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242–55.

3. Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333–43.

4. Strand V, McInnes I, Mease P, Nash P, Thom H, Kalyvas C, et al. Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis. J Comp Eff Res. 2019;8(7):497–510.

5. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–91.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oral Janus Kinase Inhibitors in Pediatric Atopic Dermatitis;Current Allergy and Asthma Reports;2024-08-06

2. Single-cell mass cytometry in immunological skin diseases;Frontiers in Immunology;2024-07-16

3. Comprehensive real-world comparisons between baricitinib and dupilumab treatments for moderate to severe atopic dermatitis;The Journal of Allergy and Clinical Immunology: In Practice;2024-07

4. Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective;Journal of Medical Economics;2023-09-07

5. Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16;Advances in Therapy;2023-06-19